Director Bernard Davitian will not stand for reelection at Lexeo's 2024 annual meeting

Lexeo Therapeutics, Inc.

Bernard Davitian notified Lexeo on April 16, 2024, that he will not seek reelection.
His departure is effective at the June 25, 2024 annual meeting of stockholders.
The decision is not due to any disagreement with the company's operations or policies.
No replacement director has been announced at this time.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bernard Davitian

Director

LXEO · Lexeo Therapeutics, Inc.

Effective: 2024-06-25
Filed: April 22, 2024, 7:59 PM ET

On April 16, 2024, Bernard Davitian notified Lexeo Therapeutics, Inc. (the “Company”) that he does not intend to stand for reelection at the Company’s 2024 annual meeting of stockholders on June 25, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bernard Davitian departed as Director at Lexeo Therapeutics, Inc..

Action: not stand for reelection
Role: Director

Exact text from the filing

On April 16, 2024, Bernard Davitian notified Lexeo Therapeutics, Inc. (the “Company”) that he does not intend to stand for reelection at the Company’s 2024 annual meeting of stockholders on June 25, 2024.

View on SEC.gov

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950123-24-003417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.